Celcuity shares rise on US launch of breast cancer drug Revtorpyk
Shares of drugmaker Celcuity rose 4.11% to $80.56 premarket after the company announced its FDA-approved breast cancer drug Revtorpyk is now commercially available in the US. The drug is approved with fulvestrant for certain patients with advanced breast cancer whose tumours do not have a PIK3CA gene mutation and whose disease worsened after hormone therapy. Citizens estimates a one-month supply will cost $30,000 and forecasts Revtorpyk sales of $6.5 million in 2026.
Celcuity said its FDA-approved breast cancer drug Revtorpyk is now commercially available in the United States. The treatment is approved with fulvestrant, with or without Pfizer's Ibrance, for certain patients with advanced breast cancer whose tumours do not have a PIK3CA gene mutation and whose disease worsened after hormone therapy. 5 million in 2026. The brokerage kept its "market outperform" rating and $177 price target, citing the drug's effectiveness and Celcuity's preparations for the launch.
Celcuity is also seeking FDA approval for Revtorpyk in patients whose tumours have PIK3CA mutations, which could broaden the drug's use. 4% year to date. 56 premarket.